Sanofi-Aventis (SNY) was the mystery bidder for the biotechnology company ImClone Systems Inc. (IMCL) , as reported by this NYTimes article.
Shares of ImClone soared last week after the company announced that Carl C. Icahn, who holds a nearly 14 percent stake in the company, had nixed a potential takeover offer of $36 a share. Icahn contended that ImClone shares were worth more than that if the company was run by competent people.
After Sanofi's identity was reported by DealBook, a NYTimes.com Web log, ImClone's stock rose just over 1 percent.
Know More about pharmaceutical companies at ThePharmVoice.com.
Comment Preview